©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Mar 24, 2016; 6(1): 125-134
Published online Mar 24, 2016. doi: 10.5500/wjt.v6.i1.125
Published online Mar 24, 2016. doi: 10.5500/wjt.v6.i1.125
Post-transplant dyslipidemia: Mechanisms, diagnosis and management
Arnav Agarwal, G V Ramesh Prasad, Division of Nephrology, Department of Medicine, University of Toronto, Toronto, ON M5C 2T2, Canada
Arnav Agarwal, G V Ramesh Prasad, Renal Transplant Program, St. Michael’s Hospital, Toronto, ON M5C 2T2, Canada
Author contributions: Agarwal A and Prasad GVR conducted the research and wrote the paper.
Conflict-of-interest statement: No potential conflict of interest. No financial support.
Correspondence to: G V Ramesh Prasad, MBBS, MSc, MA, FRCPC, FACP, FASN, Division of Nephrology, Department of Medicine, University of Toronto, 61 Queen Street East, 9th Floor, Toronto, ON M5C 2T2, Canada. prasadr@smh.ca
Telephone: +1-416-8673722 Fax: +1-416-8673709
Received: July 29, 2015
Peer-review started: July 31, 2015
First decision: October 27, 2015
Revised: November 26, 2015
Accepted: February 16, 2016
Article in press: February 17, 2016
Published online: March 24, 2016
Processing time: 232 Days and 17.4 Hours
Peer-review started: July 31, 2015
First decision: October 27, 2015
Revised: November 26, 2015
Accepted: February 16, 2016
Article in press: February 17, 2016
Published online: March 24, 2016
Processing time: 232 Days and 17.4 Hours
Core Tip
Core tip: Post-transplant dyslipidemia is highly prevalent in all solid organ transplant recipient populations. Guidelines for therapy are derived mostly from general population experiences, although the mechanisms for dyslipidemia due to immunosuppression are distinct and known. Statin therapy has understandably received the most attention in transplant populations but the potential efficacy of other therapeutic strategies should not be ignored.